RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

NCT00002462 · tracked via the Priya Life Science Germany tracker

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Phase

Phase 3

Started

1989-09

Last updated

2025-08-05

Condition(s) studied

Lymphoma

Investigational drug(s) / intervention(s)

bleomycin sulfate →doxorubicin hydrochloride →mechlorethamine hydrochlorideprednisone →procarbazine hydrochloride →vinblastine sulfate →vincristine sulfate →low-LET cobalt-60 gamma ray therapylow-LET photon therapyradiation therapy

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease.

Eligibility

Sex

ALL

Min age

15 Years

Max age

70 Years

Healthy volunteers

DISEASE CHARACTERISTICS: Histologically proven clinical or pathological Stage III/IV Hodgkin's disease Pathological Stage IIIAS disease with the spleen as the only site of subdiaphragmatic involvement excluded PATIENT CHARACTERISTICS: Age: 15 to 70 Performance status: Not specified Life expectancy: No severe limits on life expectancy due to nonmalignant disease Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No severe cardiac disease that would preclude protocol therapy Pulmonary: No severe pulmonary disease that would preclude protocol therapy Other: No severe metabolic or neurologic disease that would preclude protocol therapy No concomitant or previous second malignancy except: Nonmelanomatous skin cancer In situ carcinoma of the cervix PRIOR CONCURRENT THERAPY: No prior therapy

Primary outcome measure(s)

Benefit of adjuvant involved field RT after entering complete remission with MOPP/ABV hybrid CT
Efficacy of MOPP/ABV hybrid CT

Trial sites (56)

Facility	City	Region
Algemeen Ziekenhuis Middelheim	Antwerp	Belgium
A.Z. St. Jan	Bruges	Belgium
Hopital Universitaire Erasme	Brussels	Belgium
C.H.U. Saint-Pierre	Brussels (Bruxelles)	Belgium
Institut Jules Bordet	Brussels (Bruxelles)	Belgium
Centre Hospitalier Universitaire Brugmann	Brussels (Bruxelles)	Belgium
Centre Hospitalier Universitaire de Tivoli	La Louvière	Belgium
U.Z. Gasthuisberg	Leuven	Belgium
U.Z. Sint-Rafael	Leuven	Belgium
National Cancer Institute of Egypt	Cairo	Egypt
Institut Bergonie	Bordeaux	France
Centre Regional Francois Baclesse	Caen	France
Centre Hospitalier General	Compiègne	France
Centre Georges-Francois Leclerc	Dijon	France
Centre Leon Berard	Lyon	France
Hopital Edouard Herriot	Lyon	France
Centre Antoine Lacassagne	Nice	France
Hotel Dieu de Paris	Paris	France
Hopital Saint Antoine	Paris	France
Hopital Cochin	Paris	France
Hopital Necker	Paris	France
Hopital Jules Courmont - Centre Hospitalier Lyon Sud	Pierre-Bénite	France
Hopital Sud	Rennes	France
Centre Henri Becquerel	Rouen	France
Centre Medico-Chirurgical Foch	Suresnes	France
Centre Alexis Vautrin	Vandœuvre-lès-Nancy	France
Institut Gustave Roussy	Villejuif	France
Zentralkrankenhaus	Bremen	Germany
Centro di Riferimento Oncologico - Aviano	Aviano	Italy
Dipartimente di Oncologia di Torino	Turin (Torino)	Italy
Leyenburg Ziekenhuis	's-Gravenhage (Den Haag, the Hague)	Netherlands
Groot Ziekengasthuis 's-Hertogenbosch	's-Hertogenbosch	Netherlands
Medisch Centrum Alkmaar	Alkmaar	Netherlands
Antoni van Leeuwenhoekhuis	Amsterdam	Netherlands
Integraal Kankercentrum Amsterdam	Amsterdam	Netherlands
Slotervaart Ziekenhuis	Amsterdam	Netherlands
Onze Lieve Vrouwe Gasthuis	Amsterdam	Netherlands
Streekziekenhuizen Gooi-Noord	Blaricum	Netherlands
Catharina Ziekenhuis	Eindhoven	Netherlands
Medisch Spectrum Twente	Enschede	Netherlands

+ 16 more sites — see the full list on the official registry below.

On this site

📄 Deltasone (prednisone) drug profile →

More European Organisation for Research and Treatment of Cancer - EORTC trials in Germany

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma Recruiting

Other trials for the same condition

Better Leukemia Diagnostics Through AI (BELUGA) Recruiting

A Phase I Dose Finding Study of MB-CART2219.1 Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. Recruiting

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs Recruiting

More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00002462 on ClinicalTrials.gov ↗ ← All trials in Germany